Moderna Forecast, price target & analysts
Moderna Target price 2025 - Analyst rating & recommendation
Moderna Classifications & Recommendation:
Moderna Price Target
| Target Price | $52.00 |
| Price | $33.76 |
| Potential | 54.03% |
| Number of Estimates | 19 |
| 19 Analysts have issued a price target Moderna 2026 . The average Moderna target price is $52.00. This is 54.03% higher than the current stock price. The highest price target is $212.00 527.96% , the lowest is $25.00 25.95% . | |
| A rating was issued by 26 analysts: 5 Analysts recommend Moderna to buy, 17 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Moderna stock has an average upside potential 2026 of 54.03% . Most analysts recommend the Moderna stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2029
21 Analysts have issued a sales forecast Moderna 2025 . The average Moderna sales estimate is $2.1b . This is 34.44% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $2.7b 17.95% , the lowest is $1.5b 53.41% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $3.2b | 52.69% |
|---|---|---|
| 2025 | $2.1b | 34.44% |
| 2026 | $2.6b | 22.31% |
| 2027 | $3.3b | 28.65% |
| 2028 | $4.6b | 39.25% |
| 2029 | $7.9b | 69.14% |
9 Analysts have issued an Moderna EBITDA forecast 2025. The average Moderna EBITDA estimate is $-4.0b . This is 5.56% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $-3.2b 15.81% , the lowest is $-4.3b 14.95% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $-3.8b | 3.59% |
|---|---|---|
| 2025 | $-4.0b | 5.56% |
| 2026 | $-3.2b | 19.62% |
| 2027 | $-2.1b | 34.66% |
| 2028 | $-613m | 70.58% |
EBITDA Margin
| 2024 | -116.07% | 118.95% |
|---|---|---|
| 2025 | -186.87% | 61.00% |
| 2026 | -122.80% | 34.29% |
| 2027 | -62.36% | 49.22% |
| 2028 | -13.18% | 78.86% |
13 Moderna Analysts have issued a net profit forecast 2025. The average Moderna net profit estimate is $-4.0b . This is 10.96% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $-3.7b 2.37% , the lowest is $-4.4b 21.44% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $-3.6b | 24.88% |
|---|---|---|
| 2025 | $-4.0b | 11.08% |
| 2026 | $-3.2b | 19.15% |
| 2027 | $-2.5b | 20.88% |
| 2028 | $-1.9b | 24.36% |
| 2029 | $-1.7b | 13.97% |
Net Margin
| 2024 | -110.58% | 58.79% |
|---|---|---|
| 2025 | -187.33% | 69.41% |
| 2026 | -123.83% | 33.90% |
| 2027 | -76.16% | 38.50% |
| 2028 | -41.37% | 45.68% |
| 2029 | -21.04% | 49.14% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
13 Analysts have issued a Moderna forecast for earnings per share. The average Moderna <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $-10.30 . This is 10.99% lower than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $-9.50 2.37% , the lowest is $-11.27 21.44% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $-9.27 | 24.88% |
|---|---|---|
| 2025 | $-10.30 | 11.11% |
| 2026 | $-8.33 | 19.13% |
| 2027 | $-6.59 | 20.89% |
| 2028 | $-4.98 | 24.43% |
| 2029 | $-4.29 | 13.86% |
P/E ratio
| Current | -3.87 | 53.43% |
|---|---|---|
| 2025 | -3.49 | 9.82% |
| 2026 | -4.32 | 23.78% |
| 2027 | -5.46 | 26.39% |
| 2028 | -7.22 | 32.23% |
| 2029 | -8.39 | 16.20% |
Based on analysts' sales estimates for 2025, the Moderna stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.58 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 6.54 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 2.35 | 49.68% |
|---|---|---|
| 2025 | 3.58 | 52.33% |
| 2026 | 2.93 | 18.24% |
| 2027 | 2.27 | 22.27% |
| 2028 | 1.63 | 28.19% |
| 2029 | 0.97 | 40.88% |
P/S ratio
| Current | 4.29 | 25.33% |
|---|---|---|
| 2025 | 6.54 | 52.52% |
| 2026 | 5.35 | 18.24% |
| 2027 | 4.16 | 22.27% |
| 2028 | 2.98 | 28.19% |
| 2029 | 1.76 | 40.87% |
Current Moderna Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Buy
➜
Buy
|
Unchanged | Feb 19 2025 |
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Feb 18 2025 |
| Barclays |
Overweight
➜
Equal-Weight
|
Downgrade | Feb 18 2025 |
| B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Feb 11 2025 |
| Goldman Sachs |
Buy
➜
Neutral
|
Downgrade | Jan 29 2025 |
| Goldman Sachs |
Buy
➜
Buy
|
Unchanged | Jan 28 2025 |
| Evercore ISI Group |
In-Line
➜
In-Line
|
Unchanged | Jan 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
UBS:
Buy
➜
Buy
|
Feb 19 2025 |
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Feb 18 2025 |
|
Downgrade
Barclays:
Overweight
➜
Equal-Weight
|
Feb 18 2025 |
|
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Feb 11 2025 |
|
Downgrade
Goldman Sachs:
Buy
➜
Neutral
|
Jan 29 2025 |
|
Unchanged
Goldman Sachs:
Buy
➜
Buy
|
Jan 28 2025 |
|
Unchanged
Evercore ISI Group:
In-Line
➜
In-Line
|
Jan 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
